1 Min Read
Jan 11 (Reuters) - Hemispherx Biopharma Inc :
* Hemispherx Biopharma announces extension of Rintatolimod European early access program (eap) to pancreatic cancer patients Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.